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Despair Over Disparities
Challenges and Pathways
to “Affordable Care”*
Marvin A. Konstam, MD
Boston, Massachusetts
The Affordable Care Act attempts to address our nation’s 3
principal intertwined health care challenges: variable access,
disparate quality, and spiraling costs. Many uncertainties
remain regarding the characteristics of the system that will
evolve as we try to meet these challenges. What will be the
mix of provider funding between the public and private
sectors? Will fee-for-service reimbursement continue as the
principal payment model, or will payments be bundled for
patient groups, driving more financial risk toward providers?
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How much choice will consumers have in selecting provid-
ers for specific services? Importantly, who will choose
among the inevitable trade-offs in services—patients, pro-
viders, or payers—and what will be the basis behind these
decisions? Rationally answering these questions will require
a clear understanding of how the answers will affect health
care quality and clinical outcomes. Analyses such as that of
Kapoor et al. (1) in this issue of the Journal, examining
relationships among payment source, quality, and outcomes in
patients with heart failure, provide direction toward making
the most cogent choices.
Attention on heart failure has skyrocketed because of its
substantial contribution to health care costs as well as
morbidity and mortality, particularly among our burgeoning
older population. Optimizing quality and efficiency in car-
ing for patients with heart failure will be a key element in
any successful health care system and can provide direction
toward managing other chronic conditions. Kapoor et al. (1)
analyzed data from almost 100,000 heart failure hospital-
izations and found significant differences across 4 payer
categories: private, Medicare, Medicaid, and no insurance.
Within the investigators’ multivariate model, the Medicaid
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proven treatments, notably evidence-based beta-blockers for
patients with reduced left ventricular ejection fractions.
Compared with private insurance patients, Medicaid pa-
tients had a higher adjusted in-hospital mortality rate, as did
the no-insurance subgroup with reduced left ventricular
ejection fractions. Perhaps the most telling finding is that
Medicaid and no-insurance patients with left ventricular
ejection fractions 30% were least likely to have implant-
able cardioverter-defibrillators placed or prescribed at dis-
charge. Despite their limitations, these findings provide
important insights and direction toward reconstructing our
health care system.
The pattern of findings was not perfectly clear. For
example, angiotensin-converting enzyme inhibitors and an-
giotensin receptor blockers were least likely to be prescribed
to appropriate Medicare patients. The disparity in the
prescription of evidence-based beta-blockers did not apply
to the prescription of any beta-blockers, suggesting that
patients with Medicaid and those with no insurance may
have had a greater proportion of prescriptions for less
expensive, less proven agents. Interestingly, patients with no
insurance were most likely to receive smoking cessation
counseling and discharge instructions. As Kapoor et al. (1)
point out, the study’s limitations included dependency on
chart documentation and review and the potential influence
of unmeasurable covariates, related, for example, to the
severity of disease at time of hospitalization. The voluntary
nature of Get With the Guidelines Heart Failure may limit
the findings’ generalizability.
Although investigators refer to the patient groups as
differing in “payment model,” their findings do not provide
much information regarding the impact of various reim-
bursement models on quality or outcome. Fee-for-service
remains the predominant payment model across all payers.
Substantial variability exists regarding the nature of the
“service” unit (i.e., global hospitalization, hospital day, or
specific test or procedure) and the fee schedule, which may
be linked to the various diagnosis-related groups or to other
service categories. Variation in these models and fee struc-
tures cut across the various government and commercial
payers. The larger issue, not addressed in the current analysis,
is the relative impact of reimbursing on a fee-for-service
basis versus bundling payment for all services, over time, for
a given patient population. The designation of “private/
health maintenance organization” likely incorporates various
commercial payment models, including fee-for-service and
various degrees of capitation and provider financial risk.
As Kapoor et al. (1) point out, the observed associations
with payer type may be partly derived through differences in
socioeconomic status. The latter may influence patterns of
care seeking, care delivery, and clinical outcomes. Rathore et
al. (2), analyzing 25,000 Medicare beneficiaries hospitalized
with heart failure, found that those with lower socioeco-
nomic status had higher adjusted rates of 1-year mortality
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status. Such findings may be driven through inadequacy of
preventative strategies, delays in care resulting in higher
disease severity at the time of admission, or lesser utilization
of specialty services. Auerbach et al. (3) found that the
demographic factors of age, race, income, and educational
level of patients hospitalized with heart failure were strongly
associated with the probability of receiving care from a
cardiologist.
Issues of cost to patients and reimbursement to providers
are likely to directly influence the nature of care received.
Patients are unlikely to accept tests and treatments for
which they are uninsured and that they cannot afford.
Physicians may prescribe generic drugs rather than brand-
name drugs with a stronger evidence base, in deference to
patient affordability and probability for adherence. The
finding that is likely linked most directly to provider concern
for reimbursement is the reduced rate of implantable
cardioverter-defibrillator placement or prescription in pa-
tients with Medicaid and those with no insurance. This
critical finding exposes substantial risk to the delivery of
appropriate care, depending on how our future health care
system evolves.
In the coming years, who will decide which patients, if
any, receive a given expensive treatment? Although pres-
ently there is much focus on the development of “account-
able care organizations,” which will presumably be better
equipped to integrate and manage care efficiently, it remains
uncertain whether these organizations will continue to
receive reimbursement on a fee-for-service basis or whether
there will be a major shift toward bundling payments, with
the accountable care organizations assuming the financial
risk for the longitudinal care of populations. Under the
former condition, decisions such as who receives an expen-
sive device will be driven by payer coverage and reimburse-
ment rulings; under the latter condition, these decisions will
be left to the providers themselves.
The expansion of U.S. health care coverage is expected to
occur in part through the expansion of Medicaid eligibility.
An example of misguided policy that would drive severe
disparities in the availability of certain therapies is the recent
Arizona decision (subsequently rescinded) to deny coverage
for all forms of transplantation to Medicaid recipients. The
decision was driven purely by cost, without consideration of
effectiveness. Although robust analyses of cost-effectiveness
for heart transplantation are lacking, those analyses which
have been done (4,5) support the view that these procedures
fall well within the accepted cost-effective range, rendering
the Arizona decision irrational. Beyond coverage decisions,
payers within a fee-for-service model must reimburse cost-
effective procedures at levels that at least cover cost. In
Massachusetts, where the universal health care bill provides
a window on where the entire nation is heading, Medicaid
fees have diminished to approximately 70 cents on thedollar, with some hospitals receiving even lower payments.
As the analysis of Kapoor et al. (1) suggests, the economics
are certain to drive severe disparities in medical decision
making between patients dependent on Medicaid and those
with other forms of health coverage.
An alternative to payers issuing draconian coverage
decisions or ratcheting down reimbursement below pro-
vider cost is to bundle payments for patient populations
and allow providers to manage their overall costs, by
improving efficiency and eliminating unnecessary utiliza-
tion. Decoupling payments from specific services pro-
vided would eliminate the incentive for disparate care
provision across different patient groups. Transparency in
reporting performance on quality metrics and patient
outcomes would incentivize providers to provide appro-
priate care for all patients. As for patients, consideration
should be given to financial incentives, allowing them to
share in the global payment in return for keeping ap-
pointments and adhering to dietary and medication
prescriptions. Rather than forcing patients to settle for
less expensive but less proven drugs, or to forgo drugs
altogether, a financial structure can be found in which
patients share in the rewards of improving their own
health care quality.
Kapoor et al. (1) have provided us with insights into the
complex interplay among payers, the payment structure, and
the quality of care. They have also provided a window on the
potential for our evolving health care system to either
exacerbate or mitigate health care disparities across socio-
economic groups. Although none of the choices we face will
be easy, patients and providers alike will be far better off if
the system allows them to share in the rewards of quality
health care, rather than incentivizing the arbitrary withhold-
ing of proven management approaches.
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